Vascular calcification (VC) is a common complication in chronic kidney disease (CKD) patients and is strongly associated with the increased risk of cardiovascular diseases and all-cause mortality. Calciphylaxis is a rare type of VC with extremely high mortality, characterized by intense pain and skin damage secondary to systemic arteriolar calcification, and is most common in patients with CKD. Currently, the treatment of VC and calciphylaxis in CKD focuses on controlling risk factors and has made very little progress. SNF472 is a novel VC inhibitor that has demonstrated outstanding efficacy and safety in recent clinical trials. This review highlights the current knowledge and progress of the latest clinical research on SNF472.